August 5, 2018
FDA Grants Priority Review to Keytruda Plus Chemotherapy for Lung Cancer Subtype BookmarkEmma Shtivelman, PhD
Excerpt from Healio:
“The FDA granted priority review designation to a supplemental biologics license application that seeks approval of pembrolizumab for use in combination with chemotherapy as first-line treatment of metastatic squamous non-small cell lung cancer regardless of PD-L1 expression.
“The agency set a target action date of Oct. 30.”
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.